On World Cancer Day, do we celebrate the approval of Pfizer’s $118,200 drug Ibrance?

Today, on World Cancer Day, there has been many great announcements and celebrations.

The FDA approved Pfizer’s new drug Ibrance (INN: palbociclib) for the treatment of metastatic (advanced) breast cancer to be used in combination with letrozole based on a 165 person trial at UCLA’s cancer center. (FDA press release here, ABC story here.)

Continue Reading

Uncategorized

WTO TRIPS Council (February 2015): Norway and the United States bring gender mainstreaming to the fore-Women and Innovation

The first session of the 2015 World Trade Organization’s TRIPS Council takes place from 24 February 2015 to 25 February 2015. Like clockwork, the United States has tabled the inclusion of an additional item on Intellectual Property and Innovation. This marks the 8th time since November 2012 that the United States has submitted the inclusion of an additional agenda item to the TRIPS Council relating to intellectual property or innovation.

Continue Reading

Uncategorized

UACT letter to Professor DiMasi, asking for answer to five questions about new R&D cost study

February 4, 2015 is World Cancer Day. The rapidly increasing cost of cancer drugs should be broadly discussed. The Union for Affordable Cancer Treatment (UACT), a union of people affected by cancer (http://cancerunion.org/) is asking the author and co-author of the “Tufts Cost Study,” –a not-yet-released “study” used to justify high prices of drugs without providing data– to address the following questions:

Continue Reading

Uncategorized

EB 136 Draft decision passed on the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property

On Tuesday February 3, 2015, the final day of the 136th WHO Executive Board meeting, the EB passed a draft decision on the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property (GSPoA). The draft decision recommends to the WHA that the GSPOA be extended until 2022. Continue Reading